<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169728</url>
  </required_header>
  <id_info>
    <org_study_id>IKAST-01</org_study_id>
    <nct_id>NCT00169728</nct_id>
  </id_info>
  <brief_title>Vaccination of Children Following Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Immunogenicity of the DTaP-IPV-HBV/Hib Combination Vaccine Infanrix Hexa and the Heptavalent Pneumococcal Conjugate Vaccine Prevenar in Pediatric Recipients of Allogeneic Haematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the immunogenicity and tolerability of the
      DTaP-IPV-HBV/Hib combination vaccine Infanrix hexa and the heptavalent pneumococcal conjugate
      vaccine Prevenar in pediatric recipients of allogeneic haematopoietic stem cell
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serologic response at 1 months following primary three dose vaccination series</measure>
    <time_frame>first month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serologic response at 1 months following booster immunization</measure>
    <time_frame>first month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerability of primary and booster vaccination</measure>
    <time_frame>at least monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>identification of factors influencing immunogenicity and tolerability of study vaccines</measure>
    <time_frame>at least monthly</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">53</enrollment>
  <condition>Allogeneic Haematopoietic Stem Cell Transplantation</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>heptavalent pneumococcal conjugate vaccine, Prevenar</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pediatric recipient of allogeneic haematopoietic stem cell transplantation

          -  complete remission of underlying malignant disease (if applicable)

          -  stable haematopoietic engraftment

          -  Lansky-/Karnofsky-score &gt;= 60%

        Exclusion Criteria:

          -  primary immunodeficiency

          -  hepatitis B or C, HIV infection

          -  application of radio-/ chemotherapy following stem cell transplantation

          -  extended chronic graft-versus-host disease (Karnofsky-scale &lt; 60%)

          -  coagulopathy

          -  known allergy/hypersensitivity towards ingredients of study vaccines

          -  seizure disorder, progressive neurologic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dagmar Dilloo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Duesseldorf, Department of Pediatric Oncolgy, Hematolgy and Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children Hospital</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children Hospital</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Giessen</city>
        <zip>D-35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Jena</city>
        <zip>D-07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Muenster</city>
        <zip>D-48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Meisel R, Laws HJ, Dilloo D. Vaccination of pediatric recipients of allogeneic hematopoietic stem cell grafts using a hexavalent combination vaccine and a pneumococcal conjugate vaccine - a prospective trial of the PÄD-AG-KBT - Bone Marrow Transplantation 30(S1): S63, 2002 (abstract)</citation>
  </reference>
  <reference>
    <citation>Meisel R, Dilloo D. Pneumococcal vaccination of children after hematopoietic stem cell transplantation: timing is crucial. Clin Infect Dis. 2007 Aug 1;45(3):397-8; author reply 398-9.</citation>
    <PMID>17599322</PMID>
  </reference>
  <reference>
    <citation>Hilgendorf I, Freund M, Jilg W, Einsele H, Gea-Banacloche J, Greinix H, Halter J, Lawitschka A, Wolff D, Meisel R. Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. Vaccine. 2011 Apr 5;29(16):2825-33. doi: 10.1016/j.vaccine.2011.02.018. Epub 2011 Feb 20.</citation>
    <PMID>21345379</PMID>
  </reference>
  <results_reference>
    <citation>Meisel R, Kuypers L, Dirksen U, Schubert R, Gruhn B, Strauss G, Beutel K, Groll AH, Duffner U, Blütters-Sawatzki R, Holter W, Feuchtinger T, Grüttner HP, Schroten H, Zielen S, Ohmann C, Laws HJ, Dilloo D; Impfung von Kindern nach allogener Stammzelltransplantation (IKAST) Study Group. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2007 Mar 15;109(6):2322-6. Epub 2006 Nov 7.</citation>
    <PMID>17090650</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogeneic haematopoietic stem cell transplantation</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>children</keyword>
  <keyword>vaccination</keyword>
  <keyword>invasive pneumococcal disease</keyword>
  <keyword>tetanus</keyword>
  <keyword>diphtheria</keyword>
  <keyword>poliomyelitis</keyword>
  <keyword>pertussis</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Haemophilus influenzae type B infection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

